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Abstract
Background: It is unclear if smoking-related DNA methylation represents a causal pathway
between smoking and risk of lung cancer. We sought to identify novel smoking-related DNA
methylation sites in blood, with repeated measurements, and to appraise the putative role of
DNA methylation in the pathway between smoking and lung cancer development.
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Methods: We derived a nested case-control study from the Trøndelag Health Study
(HUNT), including 140 incident patients who developed lung cancer during 2009–13 and
140 controls. We profiled 850 K DNA methylation sites (Illumina Infinium EPIC array) in
DNA extracted from blood that was collected in HUNT2 (1995–97) and HUNT3 (2006–08)
for the same individuals. Epigenome-wide association studies (EWAS) were performed
for a detailed smoking phenotype and for lung cancer. Two-step Mendelian randomiza-
tion (MR) analyses were performed to assess the potential causal effect of smoking on
DNA methylation as well as of DNA methylation (13 sites as putative mediators) on risk
of lung cancer.
Results: The EWAS for smoking in HUNT2 identified associations at 76 DNA methylation
sites (P<5 10–8), including 16 novel sites. Smoking was associated with DNA hypome-
thylation in a dose-response relationship among 83% of the 76 sites, which was con-
firmed by analyses using repeated measurements from blood that was collected at
11 years apart for the same individuals. Two-step MR analyses showed evidence for a
causal effect of smoking on DNA methylation but no evidence for a causal link between
DNA methylation and the risk of lung cancer.
Conclusions: DNA methylation modifications in blood did not seem to represent a causal
pathway linking smoking and the lung cancer risk.
Key words: Causal inference, EWAS, Mendelian randomization
Introduction
Lung cancer has been the most common cancer type for
several decades worldwide, and it kills the largest number
of people with a 5-year survival rate of 10% globally.1
Clinical diagnostics are challenging when nodules 8 mm
are found in the lungs of patient,s as such nodules may not
be due to a malignant disease.2 Moreover, it is difficult and
not without risk to obtain tissue samples from such nod-
ules, and usually these patients are followed up with com-
puted tomography surveillance over time. As a supplement to
current standard procedures, it is important to identify bio-
markers that are associated with the risk even before cancerous
changes arise.3 In line with this, recent research has shed light
on the involvement of epigenetic modifications in cancer
development.4–6 Among the epigenetic modifications, DNA
methylation involving the addition of a methyl group to the
carbon-5 of a cytosine residue, which occurs predominantly
at CpG sites (regions of DNA where a cytosine nucleotide is
followed by a guanine nucleotide along DNA’s 5’ to 3’ di-
rection) is of particular interest as a molecular mechanism
underlying cancer risk.7
DNA methylation in blood is highly sensitive to lifestyle
influences such as smoking,8–11 and emerging evidence
suggests that it may also reflect changes in the target tissue
such as in the lung.12 Recently, Fasanelli et al. reported
that hypomethylation of smoking-related genes in blood
was associated with future onset of lung cancer.5 Since to-
bacco smoking is a causal risk factor of lung cancer,13 it is
possible that DNA methylation changes lie on the causal
pathway between smoke exposure and lung cancer risk.
Key Messages
• It was unclear if smoking-related DNA methylation represents a causal pathway for the effect of smoking on the risk
of lung cancer.
• This study identified 16 novel smoking-related DNA methylation signals. It provided further evidence that there was
no causal effect of DNA methylation in blood on lung cancer risk, by including more and novel DNA methylation
sites.
• This is the first study to apply repeated measurements of DNA methylation in blood analysed by MethylationEPIC
BeadChip (850K) to identify smoking-related DNA methylation sites.
• It is one of the few studies to assess the causal pathway between smoking, DNA methylation in blood, and the risk of
lung cancer.
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There have been some previous attempts to determine if
DNA methylation mediates the influence of lifestyle factors
on diseases.5,14 Fasanelli et al. suggested that hypomethyla-
tion in smoking-related genes AHRR and F2RL3 mediated
the effect of tobacco on lung cancer risk with large magni-
tude.5 This study, however, used observational methods that
often have limitations such as confounding and reverse causa-
tion and thus make causal inference difficult. A Mendelian
randomization (MR) approach can be applied in this context,
as it has been developed to evaluate causal relationships by
using genetic variants as instrumental variables for the expo-
sure of interest.15,16 Genetic variants at a given locus may in-
fluence methylation pattern across an extended genomic
region.17 These variants are defined as methylation quantita-
tive trait loci (mQTLs), and can be used as a proxy for meth-
ylation levels in an MR analysis.18–20
In this study, we performed epigenome-wide association
studies (EWAS) for smoking and lung cancer with repeatedly
measured DNA methylation obtained from pre-diagnostic
blood samples. The DNA methylation was assayed using the
Infinium MethylationEPIC BeadChip (Illumina Inc., CA,
USA), which can detect>850 K methylation sites. This super-
sedes the Illumina Infinium HumanMethylation450 array
which has been used in previous EWAS for smoking and lung
cancer.5,14,21,22 We also performed two-step MR analyses20
to appraise the putative causal role of DNA methylation in
the pathway between smoking and lung cancer development.
Methods
All participants gave their informed consent for participa-
tion in HUNT. The current study was approved by the
Norwegian Regional Committees for Medical and Health
Research Ethics (REK 2015/78). Ethical approval for
Generation Scotland was obtained from the Tayside
Committee on Medical Research Ethics (on behalf of the
National Health Service).
Study design and population
The Trøndelag Health Study (the HUNT Study) is one of
the largest population-based health surveys conducted in
Norway.23 The HUNT Study invited all inhabitants aged
20 years or older in the northern area of Trøndelag in four
waves: HUNT1 (1984–86), HUNT2 (1995–97), HUNT3
(2006–08) and HUNT4 (2017–19). A nested case-control
study was designed within HUNT2 and HUNT3, including
140 incident cases who developed lung cancer during
2009–13 and 140 age- (63 years) and sex-matched con-
trols. The study design and selection criteria for cases and
controls are described in Figure 1. Incident lung cancer
cases were ascertained based on the linkage of data be-
tween HUNT and the Cancer Registry of Norway. Pre-
diagnostic blood samples were collected in HUNT2 and
HUNT3 from both the cases and the controls and stored at
Figure 1 Study design of the nested case-control study from the Trøndelag Health Study (HUNT)
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80C for later use. Among the incident cases, the mean
years from blood collection to lung cancer diagnosis were
15.0 (range: 11.8–18.0) in HUNT2 and 3.8 (range: 1.0–6.7)
in HUNT3.
Genotype and lifestyle variables
Information on genotypes and lifestyle factors was extracted
from the HUNT databank.24 Information on smoking was col-
lected in both HUNT2 and HUNT3. A smoking phenotype
(seven levels) was generated taking into account the smoking
status and pack-years (pyrs): 0: never smokers; 1: former10.0
pyrs; 2: former 10.1–20.0 pyrs; 3: former20.1 pyrs; 4: current
10.0 pyrs; 5: current 10.1–20.0 pyrs; and 6: current 20.1
pyrs. A variable for change in smoking status between HUNT2
and HUNT3 [0: decrease (current to former smokers); 1: no
change (never to never and former to former); and 2: increase
(never to former, never to current, former to current and current
to current)] was generated based on status of never, former and
current smokers in the HUNT2 and HUNT3. Current to cur-
rent was classified as an increase in smoking status as exposure
to tobacco smoke had been accumulated.
Genome-wide DNA methylation analysis, quality
control and normalization
Genome-wide DNA methylation was analysed in a total of
560 pre-diagnostic blood samples that were collected from
280 study subjects on two occasions when they participated
in HUNT2 and HUNT3. About 500 ng DNA isolated from
peripheral blood cells was subject to bisulphite conversion,
using the EZ DNA methylation kit (Zymo Research, CA,
USA). Further, the DNA methylation state of over 850 K
DNA methylation sites was quantified using the Infinium
MethylationEPIC BeadChip kit (Illumina Inc., CA, USA),
according to manufacturer’s instructions. The Bead Chip
was imaged on a HiScan System (Illumina, CA, USA) and
intensity values (IDAT files) were extracted. The quality
control (QC) and functional normalization of the DNA
methylation data are described in detail in Supplementary
Material and Supplementary Figure S1, available as
Supplementary data at IJE online. After QC and functional
normalization, 864 674 DNA methylation sites in 542 sam-
ples (139 cases and 137 controls in HUNT2, 131 cases and
135 controls in HUNT3) remained for the downstream
analyses. Normalized DNA methylation estimates were pre-
sented as beta-values, ranging from 0 to 1.
Statistical analysis
All statistical analyses were performed with R (version 3.6.1)
or Stata/SE 15.1 (StataCorp, College Station, TX). A detailed
description of the statistical analyses is given in the online
Supplementary Material. Different sets of data that were used
for specific statistical analyses are described in Supplementary
Table S1, available as Supplementary data at IJE online.
First, we carried out an EWAS for the smoking pheno-
type (the seven levels) in blood samples collected from the
controls in HUNT2. Linear regressions were performed
with DNA methylation beta-values as the outcome and
smoking phenotype as the exposure. Covariates were in-
cluded in the linear regression models to adjust for the
effects of sex, age and estimated cell counts. Surrogate variable
analysis (SVA)25 was used to generate 12 variables that were
also included as covariates in the EWAS models to adjust for
batch and other technical artefacts. The P-value cut-off was set
at epigenome-wide level (5 10–8). EWAS for smoking, per-
formed with R package meffil (version 1.1.0).26
Second, to confirm the associations identified from the
EWAS for smoking, we performed an analysis using re-
peatedly measured DNA methylation data from both the
HUNT2 and the HUNT3 samples (about 11 years apart) in
relation to the smoking phenotype in HUNT2 among the
controls. A less computationally intensive strategy with
cluster-robust standard errors (LMRSE) was performed.27
We also explored the possible effect of change in smoking
status between HUNT2 and HUNT3 (categorized as de-
crease, no change or increase) on change in DNA methyla-
tion (beta-value of DNA methylation in HUNT3 minus
beta-value of DNA methylation in HUNT2) among the
controls.
Third, EWAS for lung cancer was performed among the
lung cancer cases vs controls with DNA methylation as the
exposure measured in HUNT2 and HUNT3, respectively,
and the P-value cut-off was set at 5 10–8.
Fourth, the smoking-related DNA methylation sites
that overlapped between the EWAS for smoking and the
EWAS for lung cancer in the HUNT2 samples were indi-
vidually evaluated as potential mediators between the
smoking phenotype and lung cancer, using mediation
analysis. Multiple mediators were then considered simulta-
neously, and a weighted methylation score was calculated.
Fifth, two-step MR analyses were performed. A first
step was applied to evaluate the causal effect of smoking
on DNA methylation. We used a smoking genetic score in-
cluding three single nucleotide polymorphisms (SNPs) as an
instrumental variable for the smoking phenotype: rs6265
(BDNF) associated with smoking initiation, rs1051730
(CHRNA3) with smoking quantity and rs3025343 (DBH)
with smoking cessation.28 One-sample MR using the two-
stage least square (2SLS) method was applied to investigate
a causal relationship between smoking and DNA methyla-
tion at the sites identified in the EWAS for smoking.
A second-step MR was performed to evaluate the putative
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causal association between DNA methylation and the risk of
lung cancer. We applied a two-sample MR in order to leverage
power from large genome-wide association studies (GWAS).
Instruments for the DNA methylation sites detected as putative
mediators with the mediation analyses were extracted from an
mQTL (both cis and trans) GWAS in a subset of Generation
Scotland (n¼ 5101).19,29 Summary statistics of lung cancer
GWAS were derived from McKay et al.30 with sample size 85
716 (cases 29 266 vs controls 56 450). The inverse-variance
weighted (IVW) method or Wald ratio method (when only
one mQTL as instrumental variable) was used to calculate the
causal estimates.
Results
Characteristics of study participants
Characteristics of the lung cancer cases and controls whose
DNA methylation was measured in HUNT2 and HUNT3
and passed QC are presented in Supplementary Table S2,
available as Supplementary data at IJE online. There were
more men than women (55% vs 45%). The mean age was
similar in cases and controls (56.4 vs 55.6 years in HUNT2
and 67.8 vs 66.8 years in HUNT3). About 90% of the lung
cancer cases were former or current smokers whereas
about half of the controls were never smokers in HUNT2
and HUNT3.
Identification of DNA methylation sites associated
with smoking
The EWAS for smoking in blood samples collected in
HUNT2 was performed in 128 of the 137 controls, due to
missing data on the smoking phenotype. We identified 76
(P< 510–8) DNA methylation sites (Table 1 and Figure 2;
Supplementary Figure S2, available as Supplementary data
at IJE online). The range of the effect sizes (difference in
DNA methylation beta-value per one level increase in smok-
ing phenotype) was from -0.052 to 0.030. Smoking was in-
versely associated with DNA methylation for 63 (83%) of
the 76 sites, among which cg05575921 had the strongest as-
sociation (P¼ 3.0 10–36). Top DNA methylation sites
around or within genes (5’-UTR or gene body) such as
AHRR, F2RL3, RARA, MGAT3, GPR15 and PRSS23,
were identified as being associated with smoking. Box plots
showed a dose-response association between the smoking
phenotype and DNA hypomethylation for most of the
12 top sites (P-values <5.5 10–15, Figure 3).
Among the identified 76 sites, 35 sites were exclusive to
the MethylationEPIC BeadChip compared with the
HumanMethylation450 BeadChip (Table 1). Nineteen of
the 35 EPIC BeadChip specific sites confirmed previous
smoking loci, such as F2RL3, AHRR, MGAT3, GPR15,
PRSS23, ELMSAN1 and RARA etc. Sixteen DNA methyla-
tion sites are novel signals (Table 1), and three of them were
annotated to the following genes: NBR1 (cg13849276,
P¼ 8.7 10–11), SLAMF7 (cg00045592, P¼ 2.8 10–10)
and HERC2 (cg13258799, P¼2.510–8). The remaining
13 signals were not annotated.
Confirmation of EWAS for smoking
Among the 76 sites, 75 sites (i.e. except cg23079012) were
confirmed after Bonferroni correction (actual P-val-
ue 76< 0.05) using repeated measurements with LMRSE
(n¼ 124). The results of LMRSE highly correlated with
those of a computationally intensive linear mixed effects
model (LMEM) with random intercept for randomly selected
1000 DNA methylation sites (Supplementary Figure S3, avail-
able as Supplementary data at IJE online: correlation
R¼ 0.97, P<2.2 10–16). Estimates from the EWAS for
smoking and the LMRSE analysis showed a strong correlation
for the 76 sites (R¼0.99, P< 2.2 10–16, Supplementary
Figure S4, available as Supplementary data at IJE online).
Change in smoking status between HUNT2 and HUNT3
was available for the 128 controls who were categorized as
16 with decrease (current to former), 88 with no change (59
never to never, 29 former to former), and 24 with increase
(3 never to former, 1 never to current, 6 former to current,
14 current to current) in smoking status. Of the 76 DNA
methylation sites, five sites were associated with smoking
change (Bonferroni corrected P< 0.05) and showed a dose-
response relationship (Table 2 and Figure 4). Among the
five sites, cg18110140 is a novel site.
Identification of DNA methylation sites associated
with lung cancer
When the smoking phenotype was included in the EWAS
model for lung cancer, no DNA methylation sites survived
adjustment for multiple tests (P< 5 10–8) in either
HUNT2 (139 cases vs 137 controls) or HUNT3 (131 cases
vs 135 controls). When smoking was not included in the
EWAS model to study DNA methylation sites as potential
mediators linking smoking and lung cancer, associations at
50 and 18 DNA methylation sites survived adjustment for
multiple tests in HUNT2 (Table 3; Supplementary Figure
S5, available as Supplementary data at IJE online) and
HUNT3, respectively. Of these, 30 sites from HUNT2 and
all the 18 sites from HUNT3 overlapped with the 76
smoking-related sites and 17 sites overlapped between
HUNT2 and HUNT3.
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Table 1 Epigenome-wide associations (P<5 10–8) for smoking in blood samples collected in HUNT2 in controls (n¼ 128)






cg05575921 0.052 2.97E-36 5 373378 AHRR Body
cg03636183 0.027 2.07E-27 19 17000585 F2RL3 Body
cg21566642 0.031 8.57E-26 2 233284661
cg17739917 0.020 4.04E-23 17 38477572 RARA 5’UTR Yes
cg01940273 0.021 1.65E-21 2 233284934
cg21911711 0.013 9.32E-19 19 16998668 F2RL3 TSS1500 Yes
cg05086879 0.013 2.06E-18 22 39861490 MGAT3 5’UTR Yes
cg26703534 0.013 4.74E-18 5 377358 AHRR Body
cg21161138 0.015 6.53E-18 5 399360 AHRR Body
cg17087741 0.009 8.98E-18 2 233283010
cg04180924 0.003 6.53E-17 3 98272064 Yes Yes
cg19859270 0.004 5.35E-15 3 98251294 GPR15 1st Exon
cg14391737 0.021 9.17E-15 11 86513429 PRSS23 5’UTR; Body Yes
cg18110140 0.014 1.47E-14 15 75350380 Yes Yes
cg14466441 0.004 2.92E-14 6 11392193 Yes Yes
cg09338374 0.008 3.73E-14 22 39888390 Yes Yes
cg25648203 0.011 3.95E-14 5 395444 AHRR Body
cg05284742 0.007 9.00E-14 14 93552128 ITPK1 Body
cg07943658 0.010 1.10E-13 5 352001 AHRR Body Yes
cg02978227 0.006 1.79E-13 3 98292027 Yes Yes
cg26768182 0.009 3.10E-13 9 134272679 Yes Yes
cg03329539 0.010 3.21E-13 2 233283329
cg12803068 0.030 5.12E-13 7 45002919 MYO1G Body





cg16841366 0.017 3.73E-12 2 233286192 Yes Yes
cg22812571 0.017 3.86E-12 2 233286229 Yes Yes
cg19572487 0.011 4.20E-12 17 38476024 RARA 5’UTR
cg18754985 0.004 5.75E-12 3 98237750 CLDND1 Body
cg10765427 0.007 9.99E-12 19 17005225 CPAMD8 Body Yes
cg24859433 0.008 1.13E-11 6 30720203
cg12956751 0.007 1.32E-11 2 233246922 ALPP 3’UTR Yes
cg03384915 0.005 3.62E-11 19 16986822 SIN3B Body
cg05533761 0.018 4.66E-11 11 86437953 Yes Yes
cg13849276 0.013 8.63E-11 17 41328544 NBR1 Body Yes Yes
cg21611682 0.007 2.21E-10 11 68138269 LRP5 Body
cg00045592 0.011 2.75E-10 1 160714299 SLAMF7 5’UTR; Body Yes Yes
cg00475490 0.010 3.48E-10 11 86517110 PRSS23 5’UTR; Body Yes
cg08064403 0.004 4.82E-10 3 98240258 CLDND1 Body Yes
cg04180046 0.018 6.60E-10 7 45002736 MYO1G Body
cg15342087 0.006 7.68E-10 6 30720209
cg13193840 0.007 8.11E-10 2 233285289
cg05009104 0.016 8.97E-10 7 45002980 MYO1G Body Yes
cg19885130 0.013 9.05E-10 11 68146832 LRP5 5’UTR; Body Yes
cg09935388 0.019 1.15E-09 1 92947588 GFI1 Body
cg04551776 0.008 1.17E-09 5 393366 AHRR Body
cg11660018 0.008 1.43E-09 11 86510915 PRSS23 TSS1500
cg23079012 0.004 1.55E-09 2 8343710




cg14712058 0.007 2.63E-09 19 16988083 SIN3B Body
cg22222502 0.010 2.66E-09 5 150161551 SMIM3 5’UTR Yes
(Continued)
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Mediation effects of DNA methylation on the
pathway between smoking and risk of lung cancer
The 30 smoking- and lung cancer-overlapped DNA meth-
ylation sites from HUNT2 were tested as potential media-
tors between smoking and lung cancer, among which 14
sites were identified. The relative mediation effects of the
14 DNA methylation sites and the weighted mediation
score based on the sum of the 14 sites are presented in
Table 4. The indirect effect carried by the weighted media-
tion score accounted for 61% of total effect from smoking
phenotype to lung cancer development.
Evaluation of potential causal association
between smoking and DNA methylation
Summary statistics from the first-step MR between smok-
ing and DNA methylation for the 76 DNA methylation
sites are presented in Supplementary Table S3, available as
Supplementary data at IJE online. Eleven sites showed sta-
tistical evidence for a causal association (P<0.05). The ge-
netic score explained 1.8% of the variance in smoking
with an F statistic of 2.4. To further evaluate the extent to
which the EWAS associations reflect causal effects, we
plotted the MR estimates against the EWAS estimates for
the 76 sites (Figure 5) and it showed a good correlation
(R¼ 0.74, P¼ 2.1 10–14).
Evaluation of putative causal association between
DNA methylation and lung cancer risk
The second-step MR evaluated the effect of DNA methyla-
tion on risk of lung cancer (Table 5). The 14 putative DNA
methylation mediators identified by mediation analysis are
linked to genes GPR15, AHRR, MIR4505/ELMSAN1,
RARA, F2RL3, PRSS23 and SLAMF7. We were not able
to perform MR for cg24859433 as summary statistics for
associations of its mQTLs with lung cancer were not
Table 1 Continued






cg25013095 0.001 3.63E-09 2 231809672
cg04956244 0.005 3.74E-09 17 38511592 RARA Body
cg14580211 0.010 4.07E-09 5 150161299 C5orf62 Body
cg20295214 0.006 9.28E-09 1 206226794 AVPR1B Body
cg15417641 0.019 1.36E-08 3 53700141 CACNA1D Body




cg15212295 0.005 1.55E-08 17 64710687 PRKCA Body
cg02657160 0.005 1.66E-08 3 98311063 CPOX Body
cg00592046 0.019 1.74E-08 18 69848574 Yes Yes
cg04387347 0.012 1.98E-08 16 88537187 ZFPM1 Body
cg16758086 0.007 2.17E-08 1 6173356 CHD5 Body Yes
cg14753356 0.008 2.45E-08 6 30720108
cg13258799 0.007 2.54E-08 15 28413705 HERC2 Body Yes Yes
cg14919440 0.012 3.41E-08 11 113234367 TTC12 Body Yes
cg18387338 0.006 3.45E-08 7 26591438 Yes Yes
cg03528016 0.007 3.51E-08 2 73871942 ALMS1P TSS200
cg12876356 0.015 3.73E-08 1 92946825 GFI1 Body
cg06644428 0.010 4.09E-08 2 233284112
cg25001882 0.006 4.20E-08 14 78619077 Yes Yes
cg06035956 0.003 4.24E-08 5 379099 AHRR Body Yes
cg24797066 0.005 4.34E-08 20 48407084 Yes Yes
cg20062762 0.004 4.58E-08 14 74207053 ELMSAN1 5’UTR Yes
cg12939236 0.006 4.59E-08 15 40395476 BMF Body Yes
cg16508202 0.004 4.81E-08 7 147501016 CNTNAP2 Body Yes
cg11554391 0.005 4.82E-08 5 321320 AHRR Body
cg19089201 0.016 4.91E-08 7 45002287 MYO1G 3’UTR
3’ UTR, 3’ untranslated region; 5’ UTR, 5’ untranslated region; Chr, chromosome; DNAm, DNA methylation; TSS200, up to 200 nucleotides upstream of
transcription start site; TSS1500, 200 to 1500 nucleotides upstream of transcription start site.
aCoefficient: difference in DNA methylation beta-value per level increase in smoking phenotype.
bBased on human genome reference build b37.
cBy searching the EWAS catalogue [http://www.ewascatalog.org/] and on the Pubmed per 2020–05-15.
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available.30 Both cis and trans mQTLs (range 1 to 9 per
DNA methylation site) were used as instrumental variables
for DNA methylation. The mQTLs explained 0.6% to
6.8% of the variance in DNA methylation for the included
13 sites. None of the 13 DNA methylation sites demon-
strated a causal effect on the risk of lung cancer
(Bonferroni correction: actual P-value 13> 0.05 for all,
Table 5). In addition, there was no clear correlation
(R¼ 0.083, P¼ 0.79) between the estimates derived from
the MR and EWAS for lung cancer for the 13 sites
(Supplementary Figure S6, available as Supplementary
data at IJE online). To reduce the possibility of pleiotropy
of the instrumental variables, the second-step MR was also
performed using cis-only mQTLs and it showed no causal
evidence (Supplementary Table S4, available as
Supplementary data at IJE online).
Discussion
Main findings
In this study, we identified 76 DNA methylation sites asso-
ciated with smoking, using the Illumina Infinium
MethylationEPIC BeadChip, among which 16 sites were
Figure 2 Associations between smoking and genome-wide DNA methylation in blood samples collected in HUNT2 in controls (n¼ 128). Red dots with
labels of DNA methylation sites: P<5 10–8. Effect size stands for beta value of DNA methylation per level increase of the smoking phenotype (seven
levels). HUNT: the Trøndelag Health Study
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Figure 3 Associations between smoking (horizontal axis) and DNA methylation (vertical axis) for the top 12 smoking-related DNA methylation sites.
X-axis represents seven levels of smoking phenotype [0: never smokers; 1: former 10.0 pack-years (pyrs); 2: former 10.1–20.0 pyrs; 3: former 20.1
pyrs; 4: current 10.0 pyrs; 5: current 10.1–20.0 pyrs; 6: current 20.1 pyrs]. sva: surrogate variable analysis
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novel and not captured on the older HumanMethylation450
array. Our results showed that smoking appeared to be a
causal factor for DNA methylation modifications in the blood.
There was no evidence for a causal effect of smoking-related
DNA methylation on the risk of lung cancer.
Comparison with previous studies
To our knowledge, this is the first study to use the
MethylationEPIC BeadChip to identify smoking-related
DNA methylation sites in the blood. Of the 76 sites, we
replicated 41 sites that were previously identified with
450 K.8–11 New probes on 850 K further confirmed some
previously identified smoking-related genes. Although it is
difficult to compare effect sizes in our study with those in
previous work, due to different definitions of smoking phe-
notype, the genes associated with our top DNA methyla-
tion sites are consistent with those frequently found in
previous 450 K studies, such as AHRR, F2RL3 and
PRSS23.8–11
Of the 76 DNA methylation sites, 35 were exclusive to
the MethylationEPIC BeadChip. Of the 35 sites, 19
Table 2 Associations (Bonferroni corrected P< 0.05) between change in smoking status and change in DNA methylation among
smoking-related DNA methylation sitesa
DNAm sites Coefficientb 95% CI Chromosome Position Bonferroni corrected P-value
cg05575921 0.037 0.053 0.021 5 373378 1.20E-03
cg26703534 0.020 0.029 0.011 5 377358 1.47E-03
cg17087741 0.012 0.017 0.006 2 233283010 2.80E-03
cg18110140 0.015 0.023 0.007 15 75350380 2.06E-02
cg10765427 0.012 0.017 0.007 19 17005225 8.50E-04
DNAm, DNA methylation.
aSmoking-related DNA methylation sites: the 76 sites were identified in EWAS for smoking in the cross-sectional analysis.
bCoefficient: difference in the change of DNA methylation beta-value per level increase in smoking change.
Figure 4 Associations between change in smoking status (horizontal axis) and change in DNA methylation (vertical axis) between HUNT2 and HUNT3
for the five smoking-related DNA methylation sites (Bonferroni corrected P< 0.05). Horizontal axis stands for change in smoking status [0: decrease
(from current to former smokers); 1: no change (never to never; former to former); and 2: increase (never to former; never to current; former to cur-
rent; current to current)]. HUNT: the Trøndelag Health Study; sva: surrogate variable analysis
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Table 3 Epigenome-wide associations (P<5 10–8) for lung cancer in 139 cases vs 137 controls in the HUNT2 study (n¼ 276)
DNAm sites Coefficienta SE P-value ORb Chromosome Position Gene Smoking-related
DNAm sites
cg05575921 11.854 1.603 1.43E-13 0.89 5 373378 AHRR Yes
cg21911711 33.453 4.815 3.72E-12 0.72 19 16998668 F2RL3 Yes
cg03636183 18.879 2.728 4.46E-12 0.83 19 17000585 F2RL3 Yes
cg21566642 17.334 2.512 5.21E-12 0.84 2 233284661 Yes
cg01940273 23.919 3.474 5.76E-12 0.79 2 233284934 Yes
cg17739917 24.414 3.601 1.20E-11 0.78 17 38477572 RARA Yes
cg21161138 25.790 3.892 3.44E-11 0.77 5 399360 AHRR Yes
cg24859433 39.290 5.970 4.66E-11 0.68 6 30720203 Yes
cg19572487 28.832 4.494 1.40E-10 0.75 17 38476024 RARA Yes
cg05086879 27.038 4.216 1.43E-10 0.76 22 39861490 MGAT3 Yes
cg14391737 18.074 2.837 1.88E-10 0.83 11 86513429 PRSS23 Yes
cg18110140 24.492 3.849 1.98E-10 0.78 15 75350380 Yes
cg25648203 28.854 4.557 2.43E-10 0.75 5 395444 AHRR Yes
cg11931220 42.253 6.714 3.10E-10 0.66 12 49276387
cg20174472 59.947 9.614 4.50E-10 0.55 20 61283288 SLCO4A1
cg00073090 54.425 8.762 5.25E-10 0.58 19 1265879
cg17287155 41.505 6.754 7.97E-10 0.66 5 393347 AHRR
cg19859270 68.254 11.164 9.72E-10 0.51 3 98251294 GPR15 Yes
cg03329539 30.232 4.971 1.19E-09 0.74 2 233283329 Yes
cg16841366 17.880 2.947 1.30E-09 0.84 2 233286192 Yes
cg24797066 46.647 7.695 1.35E-09 0.63 20 48407084 Yes
cg15342087 34.067 5.665 1.82E-09 0.71 6 30720209 Yes
cg09834951 51.967 8.660 1.96E-09 0.59 19 1265877
cg00475490 34.454 5.825 3.31E-09 0.71 11 86517110 PRSS23 Yes
cg00045592 25.109 4.250 3.47E-09 0.78 1 160714299 SLAMF7 Yes
cg14466441 63.619 10.773 3.51E-09 0.53 6 11392193 Yes
cg27537125 58.260 9.918 4.25E-09 0.56 1 25349681
cg27241845 24.766 4.216 4.25E-09 0.78 2 233250370
cg11660018 29.072 4.977 5.16E-09 0.75 11 86510915 PRSS23 Yes
cg17668115 30.842 5.280 5.17E-09 0.73 1 156868625 PEAR1
cg22812571 17.320 2.991 7.01E-09 0.84 2 233286229 Yes
cg26271591 19.184 3.313 7.03E-09 0.83 2 178125956 NFE2L2
cg25845814 35.177 6.118 8.96E-09 0.70 14 74224613 MIR4505; ELMSAN1 Yes
cg27650500 55.569 9.762 1.25E-08 0.57 1 25298480
cg05284742 36.017 6.332 1.29E-08 0.70 14 93552128 ITPK1 Yes
cg09935388 10.988 1.933 1.32E-08 0.90 1 92947588 GFI1 Yes
cg21901790 38.782 6.840 1.43E-08 0.68 17 46599866
cg27215690 37.380 6.594 1.44E-08 0.69 1 25344157
cg21322436 32.104 5.671 1.50E-08 0.73 7 145812842 CNTNAP2
cg04885881 25.282 4.475 1.61E-08 0.78 1 11123118
cg00310412 35.322 6.275 1.82E-08 0.70 15 74724918 SEMA7A
cg26768182 29.009 5.162 1.92E-08 0.75 9 134272679 Yes
cg23576855 6.805 1.216 2.17E-08 0.93 5 373299 AHRR
cg23771366 29.786 5.329 2.28E-08 0.74 11 86510998 PRSS23
cg12939236 29.866 5.375 2.75E-08 0.74 15 40395476 BMF Yes
cg25197654 38.281 6.932 3.34E-08 0.68 8 21914006 DMTN
cg19885130 18.171 3.313 4.14E-08 0.83 11 68146832 LRP5 Yes
cg08316204 45.510 8.303 4.23E-08 0.63 20 35973919 SRC
cg21611682 32.264 5.889 4.28E-08 0.72 11 68138269 LRP5 Yes
cg14335029 37.541 6.865 4.54E-08 0.69 9 134277886
DNAm, DNA methylation; OR, odds ratio; SE, standard error.
aCoefficient when DNA methylation beta-value changes from 0 to 1; smoking was not adjusted for in the model.
bOdds ratio of lung cancer per 1% increase of DNA methylation at the site.
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confirmed previous smoking loci and 16 were novel sig-
nals. Three of the novel sites were annotated to the follow-
ing genes: NBR1, SLAMF7 and HERC2. The protein
encoded by NBR1 functions as a specific autophagy recep-
tor31 and is associated with bilateral breast and ovarian
cancers. SLAMF7 encodes a self-ligand receptor of the sig-
nalling lymphocytic activation molecule (SLAM) family.
Activated SLAM receptors are involved in the regulation of
both innate and adaptive immune response.32 HERC2 enc-
odes a group of large proteins that are involved in neurode-
velopment, DNA damage repair and immune response.33
In line with our findings from the blood samples, DNA
hypomethylation was also identified at cg05086879
(MGAT3) and cg12956751(ALPP) in saliva of current
smokers in a previous study using the MethylationEPIC
BeadChip,34 and hypomethylation at cg24797066 was ob-
served to be related to smoking in bronchoalveolar lavage
cells.35
Our study suggested that smoking had a causal effect
on DNA methylation in the blood, which is consistent with
the findings from a recent study.36 Although our genetic in-
strument for smoking was weak, the correlation of esti-
mates derived from the MR and EWAS analyses was
moderately high. Our results did not support a causal ef-
fect of smoking-related DNA methylation in AHRR,
F2RL3 and PRSS23 on the risk of lung cancer, which con-
firmed and extended the results from a recent MR study.14
The 13 DNA methylation sites that were tested for causal
relationship with lung cancer risk in our study included
seven sites (three novel) from the EPIC BeadChip and six
from the 450 K array, whereas the aforementioned MR
study14 included 16 DNA methylation sites from the 450 K
array among which only cg05575921 overlapped with
ours. DNA methylation at cg05575921 in AHRR has been
Table 4 Mediation effect of 14 DNA methylation sitesa between smoking phenotype and risk of lung cancer
DNAm sites Total effect Indirect effect
Coefficient 95% CI Coefficient 95% CI Relative
indirect effectb
95% CI
cg19859270 0.74 0.48 0.98 0.19 0.05 0.33 0.26 0.07 0.43
cg05575921 0.71 0.47 0.95 0.36 0.00 0.74 0.51 0.01 1.00
cg25845814c 0.72 0.48 0.93 0.15 0.01 0.35 0.21 0.01 0.47
cg24859433 0.72 0.47 0.90 0.18 0.06 0.37 0.25 0.08 0.48
cg15342087 0.71 0.48 0.90 0.15 0.00 0.28 0.21 0.01 0.38
cg26768182c 0.72 0.49 0.93 0.16 0.00 0.37 0.22 0.00 0.43
cg19572487 0.74 0.51 1.00 0.22 0.11 0.35 0.29 0.13 0.48
cg24797066c 0.71 0.49 0.94 0.13 0.03 0.26 0.18 0.05 0.37
cg21911711c 0.72 0.48 1.00 0.21 0.05 0.42 0.29 0.06 0.63
cg00475490c 0.73 0.48 1.02 0.19 0.06 0.37 0.26 0.07 0.50
cg00045592c 0.70 0.47 0.96 0.14 0.03 0.31 0.20 0.04 0.40
cg03329539 0.70 0.48 0.93 0.14 0.00 0.31 0.20 0.00 0.41
cg14391737c 0.70 0.49 0.93 0.13 0.04 0.29 0.18 0.06 0.36
cg21161138 0.69 0.47 0.92 0.16 0.04 0.38 0.23 0.06 0.51
Weighted mediation scored 0.74 0.46 1.00 0.45 0.12 0.76 0.61 0.17 0.97
DNAm, DNA methylation.
a14 DNA methylation sites were identified as mediators individually with the counterfactual framework.
bIndirect effect divided by total effect.
cExclusively in EPIC Beadchip.
dThe sum of methylation beta-value at each of 14 DNA methylation sites weighted by effect size with lung cancer.
Figure 5 Correlation between Mendelian randomization and epige-
nome-wide association study estimates for smoking-DNA methylation
associations for the smoking-related 76 DNA methylation sites. The 11
sites with P< 0.05 in MR analysis are labelled
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found to be most strongly influenced by smoking in the
current and previous studies.5,10,14,21 However, there was
no clear evidence for a causal link between DNA methyla-
tion at cg05575921 and the risk of lung cancer in our
second-step MR analysis nor in the referred MR study.14
This is in contrast to previous findings by Fasanelli et al.,
who reported that hypomethylation of DNA methylation
sites in AHRR and F2RL3 may mediate the effect of to-
bacco smoking on lung cancer risk, based on observational
mediation analyses.5 Our results indicate this might have
been due to residual confounding in the previous media-
tion analysis. We also identified several other potential me-
diating DNA methylation sites near or in genes such as
RARA, GPR15, SLAMF7 and MIR4505/ELMSAN1.
Among these genes, SLAMF7 is a novel signal identified by
the EPIC array in our study. Our second-step MR analysis,
however, did not show evidence for a causal effect of
cg19572487 in RARA, cg19859270 in GPR15 or
cg25845814 in MIR4505/ELMSAN1 on the risk of lung
cancer. Nor did we find that cg00045592 in SLAMF7 was
causally associated with lung cancer risk.
Strengths and limitations
There are several strengths to our study. We used the latest
Illumina HumanMethylation EPIC BeadChip to analyse
DNA methylation, which covers over 850 K DNA methyl-
ation sites and thus provides a higher coverage compared
with the previous arrays. Blood samples used to generate
DNA methylation profiles were collected years before the
diagnosis of lung cancer. In HUNT2 this was on average
15 years before diagnosis and therefore reverse causation
was unlikely. The information on smoking status and
pack-years was recorded years before the diagnosis, which
reduced the recall bias. A detailed smoking phenotype was
derived based on both smoking quantity in total and smok-
ing status. By using the detailed smoking phenotype, a
clear dose-response association of smoking with DNA
methylation was demonstrated. To date, there have been
few studies investigating the association between smoking
and DNA methylation over time using repeated measure-
ments.10 Our study showed that smoking-related DNA
methylation was reliable: among the 76 DNA methylation
sites identified from the EWAS, 75 sites were confirmed in
the analysis using repeatedly measured DNA methylation
data. In addition, we applied two-step MR analyses to
evaluate if causal associations existed between smoking
and DNA methylation as well as between DNA methyla-
tion and lung cancer risk. Our study confirmed and ex-
tended the findings of the previous studies assessing the
above causal relationships respectively14,36 by including
more and novel methylation sites identified with the EPIC
BeadChip.
Our study also has limitations. We used the beta-values
of DNA methylation for EWAS as they have intuitively bi-
ological interpretation. However, beta-values have severe
heteroscedasticity outside the middle methylation
range.37,38 The beta difference directly obtained from the
beta-value linear regression model can give biased results
when beta-values are not between 0.2 and 0.8.38 Our study
may not have sufficient power to detect a small effect of
DNA methylation on the risk of lung cancer. This power
issue is reflected by the relatively wider 95% confidence
intervals (CIs) in Table 5. Some of the null associations
may be due to weak instrument bias, as the mQTLs
explained only 0.6% to 6.8% of the variance in DNA
methylation on the 13 CpG sites (the putative mediator
sites). In two-sample MR, weak instrument bias inclines
the association towards the null.39 Due to the small num-
ber of cases, we were not able to evaluate the causal effect
of smoking-related DNA methylation in blood on the risk
of specific histological types. Future studies are warranted
to investigate the potential causal effect of DNA methyla-
tion in blood on risk of lung cancer histological types.
In conclusion, we identified 16 novel DNA methylation
sites related to smoking, using the latest DNA methylation
array. Smoking had a causal association with DNA meth-
ylation modifications. We did not find evidence for DNA
methylation in blood being a causal factor for lung cancer
risk. However, the newly identified smoking-related DNA
methylation signals have the potential to be explored as ad-
ditional markers for smoking, to improve the early predic-
tion of lung cancer risk in future studies.
Data from the HUNT Study that are used in research
projects will, when reasonably requested by others, be
made available on request to the HUNT Data Access
Committee [hunt@medisin.ntnu.no]. The HUNT data ac-
cess information describes the policy regarding data avail-
ability [https://www.ntnu.edu/hunt/data].
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Supplementary data are available at IJE online.
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